Neuronetics (NASDAQ:STIM – Get Free Report) and Utah Medical Products (NASDAQ:UTMD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.
Profitability
This table compares Neuronetics and Utah Medical Products’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuronetics | -14.45% | -102.23% | -16.83% |
| Utah Medical Products | 30.48% | 8.83% | 8.59% |
Earnings & Valuation
This table compares Neuronetics and Utah Medical Products”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuronetics | $159.76 million | 0.68 | -$39.00 million | ($0.33) | -4.21 |
| Utah Medical Products | $38.52 million | 5.94 | $11.29 million | $3.34 | 21.55 |
Utah Medical Products has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Neuronetics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Neuronetics and Utah Medical Products, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuronetics | 1 | 0 | 4 | 0 | 2.60 |
| Utah Medical Products | 0 | 1 | 0 | 0 | 2.00 |
Neuronetics currently has a consensus target price of $5.00, indicating a potential upside of 259.71%. Given Neuronetics’ stronger consensus rating and higher probable upside, analysts plainly believe Neuronetics is more favorable than Utah Medical Products.
Institutional & Insider Ownership
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Utah Medical Products beats Neuronetics on 8 of the 14 factors compared between the two stocks.
About Neuronetics
Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.
About Utah Medical Products
Utah Medical Products, Inc. develops, manufactures and markets medical devices, with a focus on disposable products used in obstetrics, gynecology and neonatal care. Its offerings include devices and accessories for fetal monitoring, labor and delivery, newborn care and related clinical procedures. Founded in 1978 and headquartered in Midvale, Utah, the company also serves other areas of healthcare, including surgery and emergency care. Its products reach customers in the United States and international markets through a combination of direct sales and distribution channels.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
